Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma. (7th May 2019)

• Record Type: Journal Article
• Authors: Wang, Shanzong; Wang, Weijuan; Han, Xiaoguang; Wang, Youli; Ge, Yunzhen; Tan, Zhen
• Is Part Of: Journal of biochemistry. Volume 166:Number 3(2019)
• Page Start: 271
• Page End: 279
• Publication Date: 2019-05-07
• Subjects: hepatocellular carcinoma -- miR-484 -- prognosis -- TUSC5; Biochemistry -- Periodicals; Biochemistry -- Periodicals; Electronic journals; 572.05
• DOI: 10.1093/jb/mvz034
• Languages: English
• ISSNs: 0021-924X

Abstract

Abstract: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. miR-484 is previously reported to be a crucial modulator during the process from precancerous lesion to cancer. Tumour suppressor candidate 5 (TUSC5) is a potential tumour suppressor, but its expression and function in HCC are obscure. In this study, we aimed to explore the roles of miR-484 and TUSC5 in HCC, and clarify the relationship between them. We demonstrated that miR-484 was significantly up-regulated in HCC, while TUSC5 was down-regulated. TUSC5 was validated as the target gene of miR-484 and both of them were associated with the prognosis of HCC patients. miR-484 mimics markedly promoted the malignant phenotypes while TUSC5 plasmid had the opposite effect. In conclusion, miR-484/TUSC5 is potential diagnostic biomarkers and therapy targets for HCC.